CoChat

The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation

Lee, Hyun-ju, Woo, Hanwoong, Lee, Ha-Eun, Jeon, Hyongjun, Ryu, Ka-Young, Nam, Jin han, Jeon, Seong Gak, Park, HyunHee, Lee, Ji-Soo, Han, Kyung-Min, Lee, Sang Min, Kim, Jeongyeon, Kang, Ri Jin, Lee, Young-Ho, Kim, Jae-Ick, Hoe, Hyang-Sook · 2020 · Free Radical Biology and Medicine
Cited by 36

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Regulating amyloid beta (Aβ) pathology and neuroinflammatory responses holds promise for the treatment of Alzheimer's disease (AD) and other neurodegenerative and/or neuroinflammation-related diseases. In this study, the effects of KVN93, an inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase-1A (DYRK1A), on cognitive function and Aβ plaque levels and the underlying mechanism of action were evaluated in 5x FAD mice (a mouse model of AD). KVN93 treatment significantly improved long-term memory by enhancing dendritic synaptic function. In addition, KVN93 significantly reduced Aβ plaque levels in 5x FAD mice by regulating levels of the Aβ degradation enzymes neprilysin (NEP) and insulin-degrading enzyme (IDE). Moreover, Aβ-induced microglial and astrocyte activation were significantly suppressed in the KVN-treated 5xFAD mice. KVN93 altered neuroinflammation induced by LPS in microglial cells but not primary astrocytes by regulating TLR4/AKT/STAT3 signaling, and in wild-type mice injected with LPS, KVN93 treatment reduced microglial and astrocyte activation. Overall, these results suggest that the novel DYRK1A inhibitor KVN93 is a potential therapeutic drug for regulating cognitive/synaptic function, Aβ plaque load, and neuroinflammatory responses in the brain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.freeradbiomed.2020.08.030

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 36

Metadata

Authors
Lee, H.-J., Woo, H., Lee, H.-E., Jeon, H., Ryu, K.-Y., Nam, J. H., Jeon, S. G., Park, H., Lee, J.-S., Han, K.-M., Lee, S. M., Kim, J., Kang, R. J., Lee, Y.-H., Kim, J.-I., & Hoe, H.-S.
Venue
Free Radical Biology and Medicine
Publisher
Elsevier BV
Published
2020-11
Volume
160
Pages
575-595
ISSN
0891-5849 (ISSN-L)
OpenAlex
W3083272855
Cited by
36
References
25
FWCI
2.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation. https://app.cochat.ai/papers/10.1016/j.freeradbiomed.2020.08.030
The paper
Lee, H.-J., Woo, H., Lee, H.-E., Jeon, H., Ryu, K.-Y., Nam, J. H., Jeon, S. G., Park, H., Lee, J.-S., Han, K.-M., Lee, S. M., Kim, J., Kang, R. J., Lee, Y.-H., Kim, J.-I., & Hoe, H.-S. (2020). The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation. Free Radical Biology and Medicine. https://doi.org/10.1016/j.freeradbiomed.2020.08.030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.